No definition available.
Endpoint definition
↥
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
520210 |
1. Apply sex-specific ruleNone |
520210 |
2. Check conditionsNone |
520210 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters: 2 out of 7 registries used, show all original rules. |
519 |
4. Check minimum number of eventsNone |
519 |
5. Include endpointsNone |
519 |
6. Filter based on genotype QC (FinnGen only) |
519 |
Control definitions (FinnGen only)
- Control exclude
- F5_SLEEP
Extra metadata
- First used in FinnGen datafreeze
- DF5
Similar endpoints
↥List of similar endpoints to
Hypersomnia
based on the number of shared cases.
Similar with more cases:
- Sleep disorders
- Behavioural syndromes associated with physiological disturbances and physical factors
- Sleep disorders (combined)
- Psychiatric diseases
- Any event in hilmo or specialist outpatient
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 2929 | 1404 | 1508 |
| Only index persons | 2812 | 1368 | 1444 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.04 | 0.04 | 0.04 |
| Only index persons | 0.05 | 0.05 | 0.06 |
| Median age at first event (years) | |||
| Whole population | 43.74 | 39.88 | 47.34 |
| Only index persons | 43.55 | 39.80 | 47.10 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 519 | 303 | 216 |
| Unadjusted period prevalence (%) | 0.10 | 0.10 | 0.10 |
| Median age at first event (years) | 44.64 | 41.78 | 48.65 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS (R11)
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 468
- Matched controls
- 4678
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
G47.1
ICD-10 Finland
Disorders of excessive somnolence [hypersomnias]
12170.6
323.0
374
*
F51.1
ICD-10 Finland
Nonorganic hypersomnia
+∞
112.1
103
*
G47.3
ICD-10 Finland
Sleep apnoea
8.7
93.3
258
579
G47.9
ICD-10 Finland
Sleep disorder, unspecified
20.9
46.6
70
39
R06.5
ICD-10 Finland
Mouth breathing
7.3
45.6
120
210
N06BA07
ATC
modafinil; oral
63.5
40.1
46
8
R53
ICD-10 Finland
Malaise and fatigue
4.2
35.0
163
531
N06AX16
ATC
venlafaxine; oral
4.3
30.1
130
387
N06AX12
ATC
bupropion; oral
6.7
28.9
78
136
N06AB04
ATC
citalopram; systemic
3.6
28.4
154
556
G47.4
ICD-10 Finland
Narcolepsy and cataplexy
137.3
24.8
26
*
N06AX11
ATC
mirtazapine; oral
3.0
24.8
195
904
Z01.8
ICD-10 Finland
Other specified special examinations
3.3
23.9
150
591
R5140
NOMESCO Finland
Monitoring the use of the aid
4.6
23.6
88
223
F32.9
ICD-10 Finland
Depressive episode, unspecified
3.7
22.5
112
369
G25.8
ICD-10 Finland
Other specified extrapyramidal and movement disorders
11.4
21.8
41
39
N06AB06
ATC
sertraline; oral
3.9
20.9
94
282
N06BA04
ATC
methylphenidate; oral
9.5
20.8
43
49
R06.0
ICD-10 Finland
Dyspnoea
3.0
20.5
142
590
F33.10
ICD-10 Finland
Recurrent depression, moderate episode without somatic syndrome
5.5
20.4
63
129
N06AX21
ATC
duloxetine; oral
4.0
20.3
87
250
Z03.3
ICD-10 Finland
Observation for suspected nervous system disorder
5.5
19.5
60
122
Z00.4
ICD-10 Finland
General psychiatric examination, not elsewhere classified
3.8
18.2
83
251
F32.2
ICD-10 Finland
Severe depressive episode without psychotic symptoms
4.5
18.1
68
172
N05AH04
ATC
quetiapine; oral
3.0
17.6
115
454
R03AC02
ATC
salbutamol; inhalant
2.3
17.3
277
1796
R29.8
ICD-10 Finland
Other and unspecified symptoms and signs involving the nervous and musculoskeletal systems
4.0
16.1
68
192
N06AB10
ATC
escitalopram; oral
2.6
15.7
137
641
G47.2
ICD-10 Finland
Disorders of the sleep-wake schedule
+∞
15.7
15
*
UJD10
NOMESCO Finland
Esophagoscopy, gastroscopy and duodenoscopy
2.5
15.4
154
776
F33.9
ICD-10 Finland
Recurrent depressive disorder, unspecified
5.8
15.4
44
82
TAB00
NOMESCO Finland
Lumbar puncture
5.5
15.0
45
89
N06AB03
ATC
fluoxetine; oral
3.1
15.0
88
321
SHB00
NOMESCO Finland
Prepation and fitting of bite rail to mouth
3.3
14.7
78
265
GD1AA
NOMESCO Finland
Thorax X-ray examination
2.2
14.6
207
1230
F32.10
ICD-10 Finland
Moderate depressive episode without somatic syndrome
3.5
14.5
70
221
R5110
NOMESCO Finland
Evaluation of the need for aids, the testing, fitting and choice of the aid, instruction in use and delivery of it
3.3
14.4
77
262
N04BC05
ATC
pramipexole; oral
4.2
14.4
57
151
R40.0
ICD-10 Finland
Somnolence
28.2
14.4
19
7
J45.9
ICD-10 Finland
Asthma, unspecified
2.8
14.3
107
454
AA1BG
NOMESCO Finland
Standard MRI examination of brain with high intensity magnet
3.6
14.0
65
198
N03AX09
ATC
lamotrigine; oral
4.6
13.8
49
117
R01AD09
ATC
mometasone; nasal
2.1
13.4
237
1531
A02BC02
ATC
pantoprazole; systemic
2.1
13.3
298
2127
N06AG02
ATC
moclobemide; oral
5.0
13.1
42
90
R51.80
ICD-10 Finland
Headache
2.7
13.1
97
407
R03DC03
ATC
montelukast; oral
2.7
13.0
97
408
XA420
NOMESCO Finland
Extensive sleep examination
13.5
13.0
22
17
J45.1
ICD-10 Finland
Nonallergic asthma
4.2
13.0
50
129
A02BC03
ATC
lansoprazole; oral
2.3
12.5
144
762
R10.4
ICD-10 Finland
Other and unspecified abdominal pain
2.1
12.4
184
1092
P06
ICPC
Sleep disturbance
3.2
12.3
69
242
N06AX18
ATC
reboxetine; oral
12.9
12.2
21
17
N03AX16
ATC
pregabalin; oral
2.3
12.2
129
658
H02AB06
ATC
prednisolone; systemic
2.0
12.2
225
1464
G47.8
ICD-10 Finland
Other sleep disorders
18.7
12.1
18
10
F33.2
ICD-10 Finland
Recurrent depressive disorder, current episode severe without psychotic symptoms
4.3
11.9
44
110
H03AA01
ATC
levothyroxine sodium; systemic
2.3
11.8
121
606
F31.9
ICD-10 Finland
Bipolar affective disorder, unspecified
7.0
11.6
28
42
R03CA02
ATC
ephedrine; oral
+∞
11.5
11
*
214
Kela drug reimbursment
Severe and chronic narcolepsy
122.9
11.5
12
*
N06AA09
ATC
amitriptyline; systemic
3.1
11.1
63
224
P03
ICPC
Feeling depressed
2.9
11.1
71
273
J45
ICD-10 Finland
Asthma
3.2
11.0
59
201
M54.5
ICD-10 Finland
Low back pain
2.0
10.9
168
1006
R07.4
ICD-10 Finland
Chest pain, unspecified
2.2
10.8
130
697
203
Kela drug reimbursment
Chronic asthma and similar chronic obstructive pulmonary diseases
2.4
10.8
104
501
F31.8
ICD-10 Finland
Other bipolar affective disorders
8.5
10.4
22
27
AA1AD
NOMESCO Finland
CT of head and brain
2.3
10.3
113
579
F34.1
ICD-10 Finland
Dysthymia
5.0
10.3
32
67
EB1HA
NOMESCO Finland
Panorama tomography of teeth and jaws or similar X-ray examination
1.9
10.2
207
1366
N03AX12
ATC
gabapentin; oral
2.5
10.1
87
396
P76
ICPC
Depressive disorder
3.4
10.1
48
150
J45.0
ICD-10 Finland
Predominantly allergic asthma
3.0
9.8
57
206
F51.0
ICD-10 Finland
Nonorganic insomnia
2.7
9.7
70
289
F33.11
ICD-10 Finland
Recurrent depression, moderate episode of somatic syndrome
5.9
9.6
26
46
R03BB04
ATC
tiotropium bromide; inhalant
3.2
9.6
50
167
N02BE01
ATC
paracetamol; systemic, rectal
2.2
9.6
397
3360
N06AX26
ATC
vortioxetine; oral
3.5
9.5
44
134
A02BC05
ATC
esomeprazole; systemic
1.9
9.5
187
1211
N06AX03
ATC
mianserin; oral
4.2
9.5
35
88
282
Kela drug reimbursment
Sodium oxybat
+∞
9.4
9
*
F60.5
ICD-10 Finland
Anankastic personality disorder
9.8
9.3
18
19
G04BD04
ATC
oxybutynin; oral, transdermal
4.8
9.3
30
66
M79.6
ICD-10 Finland
Pain in limb
1.9
9.2
166
1038
N05AX12
ATC
aripiprazole; systemic
4.4
9.2
32
76
SPAT1223
SPAT
Implementation of physical therapy rehabilitation plan
2.0
9.1
137
797
A02BC01
ATC
omeprazole; systemic
2.0
9.0
133
767
C07AB07
ATC
bisoprolol; oral
1.9
9.0
193
1281
M01AE03
ATC
ketoprofen; systemic, rectal
1.9
8.9
178
1152
J01AA02
ATC
doxycycline; systemic
1.9
8.9
360
2957
J46
ICD-10 Finland
Status asthmaticus
6.1
8.9
23
39
R96
ICPC
Asthma
3.0
8.9
51
183
N04BD01
ATC
selegiline; oral
9.7
8.8
17
18
R35
ICD-10 Finland
Polyuria
3.7
8.8
38
110
SAA01
NOMESCO Finland
Simple examination of mouth
1.9
8.8
342
2762
3472A
ICD-9 Finland
Cataplexy and narcolepsy[OBSTRUKTIIVINEN UNIAPNEA]
10.3
8.6
16
16
R41.8
ICD-10 Finland
Other and unspecified symptoms and signs involving cognitive functions and awareness
3.2
8.6
44
146
SPAT1263
SPAT
Sampling
1.8
8.5
203
1392
N05BA04
ATC
oxazepam; oral
2.0
8.4
122
701
Z01.5
ICD-10 Finland
Diagnostic skin and sensitization tests
2.6
8.4
60
247
N02AX02
ATC
tramadol; systemic, rectal
1.8
8.3
192
1297
N02AE01
ATC
buprenorphine; parenteral, sublingual, transdermal
2.7
8.3
56
222
C07AA05
ATC
propranolol; systemic
2.1
8.3
102
547
N05CF01
ATC
zopiclone; oral
1.9
8.3
140
850
R42
ICD-10 Finland
Dizziness and giddiness
2.2
8.2
94
487
A09
ICD-10 Finland
Other gastroenteritis and colitis of infectious and unspecified origin
2.2
8.2
88
443
N03AG01
ATC
valproic acid; systemic, rectal
3.3
8.2
40
128
E66.00
ICD-10 Finland
Metabolic syndrome
3.7
8.2
35
101
F43.1
ICD-10 Finland
Post-traumatic stress disorder
4.8
8.1
26
57
AA40B
NOMESCO Finland
NA
17.5
8.1
12
7
R02
ICPC
Shortness of breath/dyspnoea
2.6
8.1
60
249
N04BA02
ATC
levodopa and decarboxylase inhibitor; oral
6.1
8.1
21
36
J01CR02
ATC
amoxicillin and beta-lactamase inhibitor; systemic
1.7
8.0
251
1863
F32.11
ICD-10 Finland
Moderate depressive episode with somatic syndrome
4.3
7.9
28
68
F41.2
ICD-10 Finland
Mixed anxiety and depressive disorder
2.7
7.9
56
227
Z71.3
ICD-10 Finland
Dietary counselling and surveillance
3.6
7.9
34
99
N06AB05
ATC
paroxetine; oral
3.1
7.9
44
153
L03
ICPC
Low back symptom/complaint
2.0
7.8
115
662
N05CF02
ATC
zolpidem; oral
2.1
7.8
91
476
E66.8
ICD-10 Finland
Other obesity
3.4
7.8
36
111
112
Kela drug reimbursment
Severe psychotic and other severe mental disorders
3.0
7.8
44
156
R06AX27
ATC
desloratadine; oral
1.9
7.7
141
877
G04BD07
ATC
tolterodine; oral
4.9
7.7
24
51
AA1CG
NOMESCO Finland
Extensive MRI examination of brain with high intensity magnet
2.9
7.7
45
163
SHA02
NOMESCO Finland
Correction of physiology of bite - basic therapy visit
2.9
7.7
45
164
M03BX02
ATC
tizanidine; oral
1.7
7.7
293
2292
G47.0
ICD-10 Finland
Disorders of initiating and maintaining sleep [insomnias]
6.9
7.7
18
27
NA1BG
NOMESCO Finland
Cervical spine MRI examination with high intensity magnet
3.5
7.6
35
107
J01FA06
ATC
roxithromycin; oral
1.8
7.6
186
1270
WZB00
NOMESCO Finland
Telephone receipt or other advice
1.8
7.5
148
942
N05BA01
ATC
diazepam; systemic, rectal
2.3
7.5
70
328
F41.1
ICD-10 Finland
Generalized anxiety disorder
3.3
7.5
36
114
R03BA01
ATC
beclometasone; inhalant
2.3
7.5
70
330
N02AA59
ATC
codeine, combinations excl. psycholeptics; systemic
1.7
7.5
217
1561
WX722
NOMESCO Finland
PEEP
3.6
7.5
32
93
A04
ICPC
Weakness/tiredness general
2.4
7.4
65
298
IAB13
NOMESCO Finland
Psychiatric sleep disorder consultation
+∞
7.3
7
*
R03BA05
ATC
fluticasone; inhalant
2.1
7.3
91
487
K07.60
ICD-10 Finland
Snapping jaw
3.4
7.3
34
106
J01.0
ICD-10 Finland
Acute maxillary sinusitis
1.9
7.2
115
678
N05AX08
ATC
risperidone; systemic
3.0
7.2
41
146
Z03.80
ICD-10 Finland
Observation for other suspected diseases and conditions
4.2
7.2
26
65
L28
ICPC
Limited function/disability (L)
2.3
7.2
68
323
N03AE01
ATC
clonazepam; systemic
3.3
7.2
35
113
G44.2
ICD-10 Finland
Tension-type headache
2.2
7.1
70
340
A02BA02
ATC
ranitidine; systemic
2.1
6.9
85
451
J31.0
ICD-10 Finland
Chronic rhinitis
2.8
6.9
43
162
P29
ICPC
Psychological sympt/compl other
2.9
6.8
40
146
R06AE07
ATC
cetirizine; oral
1.7
6.8
211
1532
R03AK07
ATC
formoterol and budesonide; inhalant
2.0
6.8
97
551
R01AD01
ATC
beclometasone; nasal
2.1
6.8
80
420
SBB10
NOMESCO Finland
Teeth copy
2.9
6.7
39
142
R10.1
ICD-10 Finland
Pain localized to upper abdomen
2.1
6.7
76
393
JDF11
NOMESCO Finland
Laparoscopic gastric bypass
6.6
6.7
16
25
M03BC51
ATC
orphenadrine, combinations; systemic
1.8
6.7
135
860
C01DA08
ATC
isosorbide dinitrate; oral, oral aerosol, sublingual, transdermal
2.1
6.7
83
443
Z50.8
ICD-10 Finland
Care involving use of other rehabilitation procedures
3.0
6.6
38
136
SHA03
NOMESCO Finland
Correction of physiology of bite - demanding therapy visit
3.7
6.6
27
76
EB1AA
NOMESCO Finland
Tooth X-ray examination
1.7
6.6
260
2015
R01AD08
ATC
fluticasone; nasal
1.8
6.5
141
917
WZC10
NOMESCO Finland
Extensive specialist consultion with written report
3.4
6.5
30
93
N05AA02
ATC
levomepromazine; systemic
3.7
6.5
27
77
A06AC01
ATC
ispaghula (psylla seeds); oral
1.9
6.5
103
606
R06AX22
ATC
ebastine; oral
2.0
6.4
87
480
N07XX04
ATC
sodium oxybate; oral
70.7
6.4
7
*
J34.2
ICD-10 Finland
Deviated nasal septum
3.0
6.4
36
126
WX110
NOMESCO Finland
Local anesthesy
1.7
6.4
321
2646
SPAT1230
SPAT
Aid fitting and borrowing and monitoring of use
2.0
6.4
78
416
R03AC12
ATC
salmeterol; inhalant
4.1
6.4
23
58
M54.9
ICD-10 Finland
Dorsalgia, unspecified
2.3
6.4
58
270
WZC00
NOMESCO Finland
Planning of intervention or health care consultation
1.7
6.3
153
1032
J20.9
ICD-10 Finland
Acute bronchitis, unspecified
2.0
6.3
79
425
R51
ICD-10 Finland
Headache
3.1
6.3
32
107
WYA10
NOMESCO Finland
First aid or other corresponding healthcare contact
2.6
6.3
44
179
M79.7
ICD-10 Finland
Fibromyalgia
4.0
6.3
23
59
IEY18
NOMESCO Finland
Psychiatric sleep coaching, individual
+∞
6.3
6
*
G93.3
ICD-10 Finland
Postviral fatigue syndrome
27.1
6.2
8
*
DHB50
NOMESCO Finland
Turbinoplasty
5.2
6.2
18
36
R03AK06
ATC
salmeterol and fluticasone; inhalant
2.2
6.2
64
315
SFA40
NOMESCO Finland
Replacement of krone of tooth
1.9
6.2
99
580
DJD20
NOMESCO Finland
Plastic repair of septum of nose
3.3
6.1
29
92
SPAT1301
SPAT
No procedures
1.7
6.1
143
952
F33.00
ICD-10 Finland
Recurrent depression, mild episode without somatic syndrome
5.0
6.1
18
37
Z03.89
ICD-10 Finland
Observation for other suspected diseases and conditions
2.1
6.0
65
327
N06AX17
ATC
milnacipran; oral
6.2
6.0
15
25
R55
ICD-10 Finland
Syncope and collapse
2.5
6.0
48
208
SFC01
NOMESCO Finland
Adjuvant procedure of filling therapy
1.8
6.0
127
820
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
51
106
5.23
23.70
1.1
1.2
415.3
454.7
mg/l
0.34
51
99
107
391
3.19
22.77
2.3
2.0
345.4
365.4
nmol/l
0.59
99
367
255
1488
2.40
21.10
2.2
1.9
101.1
95.2
pmol/l
1.05
148
778
44
92
5.13
20.26
1.3
1.3
37.1
1393.3
e6/l
0.60
39
75
436
3289
3.04
20.12
5.7
3.9
14.7
14.6
pmol/l
0.29
410
3005
294
1890
2.28
18.63
6.7
7.0
1.2
1.2
mmol/l
0.25
239
1615
42
92
4.88
18.31
1.2
1.2
2.8
14.9
e6/l
0.89
36
72
202
1131
2.29
17.63
4.3
3.5
0.0
0.0
estimate
0.69
71
416
413
3125
2.57
17.16
4.6
3.9
11.0
10.4
mm/h
0.38
388
2888
129
615
2.46
16.07
1.9
1.7
1446.2
1217.0
nmol/l
1.43
103
476
265
1703
2.14
15.95
6.3
6.4
1.2
1.2
mmol/l
0.14
240
1558
255
1631
2.11
15.36
4.2
5.0
36.2
36.2
g/l
0.02
241
1511
200
1166
2.16
15.36
2.6
2.1
129.6
244.2
u/l
1.28
184
1105
109
491
2.54
15.26
7.6
6.1
—
—
—
0
0
211
1271
2.11
14.75
2.5
3.3
2.4
2.3
mmol/l
0.08
192
1131
475
3962
3.35
14.45
6.8
4.5
1.7
2.1
mu/l
0.89
444
3655
147
780
2.23
14.10
1.6
1.6
456.9
432.7
pmol/l
0.56
116
663
72
276
2.87
13.77
4.3
3.7
4.3
4.6
pmol/l
2.44
57
249
286
1975
2.00
13.28
3.6
2.7
113.0
107.1
ug/l
0.14
273
1832
252
1676
1.98
12.93
2.5
2.3
77.1
75.1
nmol/l
0.50
237
1510
208
1301
2.00
12.67
2.5
2.6
54.1
57.8
u/l
0.98
195
1203
222
1429
1.97
12.38
3.4
2.9
—
—
—
0
0
331
2453
1.96
12.00
8.6
9.0
4.0
4.1
e9/l
0.85
302
2161
404
3219
2.15
11.87
6.9
7.5
75.6
76.3
u/l
0.14
384
3011
19
31
6.32
11.27
1.2
1.0
—
—
—
0
0
122
652
2.14
11.21
2.6
2.7
2.4
2.4
mmol/l
0.17
112
572
354
2716
1.95
11.20
5.0
4.0
64.2
234.0
e6/l
—
6
40
164
981
1.98
11.07
2.6
2.0
3.2
3.0
mg/l
0.36
151
845
220
1465
1.87
10.66
4.0
3.3
383.9
33.5
ng/l
0.52
140
947
106
548
2.17
10.55
2.1
2.3
2.4
2.4
g/l
0.52
96
506
169
1036
1.94
10.54
1.4
1.3
1.4
2.1
u/ml
0.45
51
298
96
478
2.24
10.48
4.1
6.0
1.0
1.0
mmol/l
0.14
89
442
287
2088
1.84
10.37
5.3
4.6
0.0
0.0
estimate
0.50
79
424
240
1653
1.84
10.36
4.3
3.4
—
—
—
0
0
286
2084
1.83
10.22
4.2
3.3
0.0
0.0
estimate
0.00
76
413
162
995
1.91
9.95
3.7
3.1
852.3
932.0
ng/l
0.13
135
845
287
2115
1.80
9.68
4.2
3.3
0.0
0.0
estimate
0.50
74
403
188
1231
1.83
9.34
3.8
3.1
8.3
8.1
mmol/l
0.24
159
1042
110
603
2.05
9.31
2.1
2.3
13.8
13.9
umol/l
0.03
99
554
128
741
1.97
9.29
1.4
1.3
18.7
36.3
iu/ml
2.34
37
228
66
295
2.42
9.20
2.7
2.3
3.9
7.9
ug/l
2.24
54
266
471
4125
2.53
9.03
5.3
4.2
6.0
5.8
mmol/l
1.38
434
3802
490
4381
3.12
8.90
19.6
14.0
139.7
139.7
mmol/l
0.10
477
4260
490
4394
3.06
8.59
19.7
14.1
4.0
4.0
mmol/l
1.08
477
4266
45
173
2.75
8.52
1.4
1.3
1.0
2.0
u/ml
—
5
15
309
2382
1.73
8.41
5.4
4.9
6.5
6.6
mmol/l
0.29
290
2194
60
268
2.40
8.37
2.6
3.7
71.5
72.7
ng/l
0.05
52
245
150
943
1.83
8.35
1.8
1.8
0.9
1.1
mg/l
0.55
108
702
139
860
1.84
8.12
1.5
1.5
20.4
20.5
nmol/l
0.01
126
736
59
267
2.36
7.99
1.3
1.2
200.9
254.1
u/ml
0.20
54
240
94
515
2.01
7.89
2.2
2.3
24.1
24.0
%
0.04
80
443
54
238
2.42
7.75
2.9
3.3
1.8
1.7
mmol/l
0.07
39
175
56
254
2.35
7.54
3.1
3.2
5.3
5.1
kpa
0.87
50
238
144
921
1.78
7.46
4.9
3.5
1.0
1.0
kg/l
0.66
16
129
119
719
1.85
7.43
1.5
1.3
5.7
10.4
u/ml
0.52
54
293
443
3861
2.01
7.36
6.9
5.2
39.3
39.2
mmol/mol
0.04
408
3622
278
2134
1.65
7.24
5.1
6.6
9.8
11.1
umol/l
2.18
265
2014
483
4360
2.55
7.22
17.1
12.5
18.4
22.2
mg/l
2.17
396
3363
159
1057
1.73
7.16
2.4
2.7
6507.7
7208.3
umol/l
0.06
132
926
163
1094
1.71
7.08
3.1
2.8
0.3
0.4
e6/l
1.01
130
823
45
191
2.48
7.01
1.3
1.5
471.1
293.1
mu/l
0.67
39
174
102
615
1.82
6.34
2.1
1.8
1.6
1.4
%
1.42
93
547
102
620
1.80
6.17
2.5
3.6
0.8
0.8
mmol/l
0.05
93
591
498
4613
2.97
6.11
11.8
9.9
35.7
26.6
u/l
0.77
480
4468
166
1159
1.64
6.05
4.7
4.0
9.8
10.3
mg/mmol
0.06
108
746
55
277
2.10
5.76
1.4
1.3
—
36.5
—
0
18
63
338
1.98
5.57
1.2
1.2
117.0
170.2
iu/ml
0.52
21
143
12
25
4.89
5.52
1.1
1.0
318.2
232.1
ng/l
—
5
15
12
25
4.89
5.52
1.1
1.0
913.4
593.2
ng/l
—
5
15
195
1443
1.56
5.46
3.1
3.4
58.1
30.9
u/l
0.43
186
1378
360
3069
1.56
5.15
3.6
3.1
41.9
44.6
u/l
0.44
339
2900
449
4082
1.74
4.50
14.6
11.3
85.8
86.4
ml/min/173m2
0.20
379
3339
55
304
1.91
4.47
2.9
3.8
1.2
1.2
mmol/l
0.13
47
266
27
114
2.44
4.31
1.5
1.5
301.6
290.6
ug/g
0.08
15
68
49
268
1.91
4.12
1.3
1.6
—
—
—
0
0
30
136
2.28
4.10
1.9
1.7
—
—
—
0
0
44
233
1.97
4.06
3.0
2.3
812.8
3493.3
u/l
1.08
13
103
16
53
3.08
3.99
1.2
1.1
—
—
—
0
0
16
54
3.03
3.88
1.1
1.1
—
—
—
0
0
247
2018
1.43
3.87
4.0
4.1
—
—
—
0
0
44
240
1.91
3.74
2.2
3.0
116.2
166.3
ng/l
0.68
38
215
65
408
1.68
3.48
9.1
9.8
1.7
1.3
mmol/l
0.48
53
332
40
224
1.85
3.17
6.3
8.7
25.8
24.7
mmol/l
1.08
40
211
47
280
1.75
3.05
2.9
2.9
4.2
4.6
kpa
1.00
47
274
56
352
1.66
3.00
9.9
10.7
127.0
121.4
g/l
1.12
56
342
31
164
1.95
2.92
2.4
2.4
—
—
—
0
0
25
122
2.10
2.92
1.8
1.3
6.3
12.6
u/ml
—
5
25
(3020427) Coagulation factor X inhibitor [Units/volume] in Platelet poor plasma by Coagulation assay
22
102
2.21
2.91
2.7
2.4
0.4
0.3
u/ml
0.23
11
53
456
4264
1.57
2.88
5.1
4.2
4.6
4.7
mmol/l
1.47
417
3993
442
4107
1.51
2.86
4.6
3.7
1.4
1.3
mmol/l
2.77
406
3817
460
4320
1.57
2.73
5.6
4.6
2.7
2.8
mmol/l
1.10
418
4019
453
4243
1.53
2.69
5.1
4.1
1.4
1.5
mmol/l
1.93
412
3950
35
199
1.81
2.67
1.4
1.9
3.1
3.8
mg/l
0.24
26
139
16
67
2.43
2.65
3.3
2.4
18.0
16.9
%
0.53
11
33
12
44
2.77
2.56
1.0
1.1
—
—
—
0
0
27
143
1.94
2.56
2.4
1.8
43.0
36.9
nmol/l
0.50
27
138
5
8
6.30
2.37
1.0
1.0
—
—
—
0
0
5
8
6.30
2.37
1.0
1.0
—
—
—
0
0
17
78
2.22
2.33
2.3
3.6
3.3
4.4
e9/l
1.47
17
78
506
4904
2.27
2.33
26.7
18.5
136.9
136.6
g/l
0.22
497
4842
50
327
1.59
2.32
3.1
3.6
6.1
5.8
kpa
1.78
50
321
89
659
1.42
2.29
3.0
2.5
1.0
1.0
e6/l
0.11
54
378
21
106
2.02
2.29
1.6
1.4
—
—
—
0
0
49
321
1.58
2.26
3.1
3.7
3.1
1.9
mmol/l
1.62
41
260
23
121
1.94
2.24
1.3
1.1
—
—
—
0
0
20
100
2.04
2.23
1.8
1.1
—
—
—
0
0
17
80
2.16
2.21
2.4
3.9
54.6
57.2
%
0.33
17
80
23
122
1.93
2.19
1.3
1.1
—
—
—
0
0
8
24
3.37
2.19
1.0
1.2
—
—
—
0
0
9
30
3.03
2.15
1.0
1.5
13.9
13.0
umol/l
—
9
30
58
400
1.51
2.14
3.7
2.9
—
—
—
0
0
82
606
1.42
2.13
2.1
1.9
—
—
—
0
0
59
409
1.50
2.13
1.8
1.9
—
—
—
0
0
38
238
1.64
2.11
1.1
1.0
—
—
—
0
0
58
403
1.49
2.07
1.7
1.8
—
—
—
0
0
5
11
4.58
1.94
1.2
1.0
—
—
—
0
0
5
11
4.58
1.94
1.2
1.0
97.0
106.1
%
—
5
11
8
27
2.99
1.94
1.4
1.6
—
28.6
—
0
5
8
27
2.99
1.94
1.1
1.1
—
—
—
0
0
21
114
1.88
1.90
1.1
1.1
—
—
—
0
0
21
115
1.86
1.85
1.4
1.3
—
—
—
0
0
93
720
1.36
1.84
2.0
2.2
—
—
—
0
0
26
153
1.74
1.83
1.2
1.6
—
—
—
0
0
8
29
2.79
1.80
1.3
4.1
92.0
98.3
%
—
8
29
22
124
1.81
1.78
1.3
2.3
3.0
3.1
g/l
0.06
17
99
46
315
1.51
1.78
2.4
2.5
59.3
69.7
ml/min/173m2
1.70
21
141
(3011547) Coagulation factor VII activity actual/normal in Platelet poor plasma by Coagulation assay
6
18
3.36
1.75
1.2
1.0
125.2
130.2
%
—
6
18
6
18
3.36
1.75
1.5
1.4
—
—
—
0
0
400
3742
1.30
1.75
18.6
15.1
13.5
13.6
%
0.70
395
3679
(40770918) von Willebrand factor (vWf).activity actual/normal in Platelet poor plasma by Immunoassay
7
24
2.94
1.72
1.3
2.0
101.1
125.6
%
—
7
24
339
3113
1.26
1.70
3.0
3.4
—
—
—
0
0
10
42
2.41
1.68
1.7
1.2
—
—
—
0
0
20
112
1.82
1.67
2.3
2.8
—
—
—
0
0
25
151
1.69
1.63
1.4
2.2
1.9
1.4
g/l
1.66
20
133
5
14
3.60
1.62
1.0
1.1
—
—
—
0
0
5
14
3.60
1.62
1.0
1.2
—
—
—
0
0
27
167
1.65
1.61
2.6
3.7
25.6
24.1
mmol/l
1.19
22
156
11
50
2.23
1.58
3.1
1.8
—
—
—
0
0
17
92
1.88
1.57
1.2
1.2
213.2
251.2
u/ml
0.31
12
56
37
249
1.52
1.57
1.6
1.4
19.5
24.6
iu/l
0.50
32
213
5
15
3.35
1.52
1.0
1.3
—
—
—
0
0
5
15
3.35
1.52
1.0
1.1
—
—
—
0
0
5
15
3.35
1.52
1.0
1.3
—
—
—
0
0
(3016894) Varicella zoster virus DNA [Presence] in Cerebral spinal fluid by NAA with probe detection
7
27
2.61
1.52
1.0
1.2
—
—
—
0
0
96
770
1.30
1.50
1.5
1.5
—
—
—
0
0
11
52
2.14
1.45
1.0
1.3
—
—
—
0
0
22
133
1.68
1.45
1.3
2.2
7.9
7.3
g/l
0.70
17
104
22
133
1.68
1.45
1.3
2.2
—
—
—
0
0
49
357
1.41
1.42
1.5
2.6
0.2
0.2
g/l
0.04
44
334
54
401
1.39
1.41
3.7
4.5
237.9
253.3
u/l
0.55
49
381
9
40
2.27
1.40
3.7
1.7
—
—
—
0
0
9
40
2.27
1.40
3.7
1.7
—
—
—
0
0
9
40
2.27
1.40
3.7
1.7
—
—
—
0
0
17
96
1.80
1.40
1.2
1.2
—
—
—
0
0
11
53
2.10
1.39
1.6
1.6
—
—
—
0
0
5
17
2.96
1.36
1.2
1.2
—
—
—
0
0
86
695
1.28
1.28
4.0
3.5
166.1
328.7
ng/l
0.62
63
500
21
133
1.60
1.19
1.3
2.2
4.6
3.7
g/l
1.34
16
98
8
39
2.07
1.15
1.4
1.2
—
72.2
—
0
5
8
39
2.07
1.15
1.4
1.7
—
—
—
0
0
80
650
1.27
1.15
1.9
2.0
—
—
—
0
0
5
20
2.51
1.15
1.0
1.2
112.6
169.1
iu/ml
—
5
20
5
20
2.51
1.15
5.8
3.8
259.2
90.9
nmol/l
—
5
20
13
75
1.75
1.03
1.7
1.6
—
—
—
0
0
12
68
1.78
1.01
1.7
1.6
—
—
—
0
0
12
68
1.78
1.01
1.2
1.1
—
—
—
0
0
5
23
2.18
0.98
1.0
1.1
92.5
121.1
u/l
—
5
15
5
23
2.18
0.98
1.0
1.1
20.5
43.9
u/l
—
5
15
7
36
1.96
0.97
3.1
2.0
17.2
17.5
ug/l
—
7
36
7
37
1.90
0.94
1.3
1.0
—
—
—
0
0
7
37
1.90
0.94
2.7
2.2
—
—
—
0
0
6
27
2.24
0.93
2.2
1.4
—
—
—
0
0
18
118
1.54
0.92
1.7
2.0
1.6
6.5
iu/l
—
7
43
8
45
1.79
0.84
3.9
1.9
—
—
—
0
0
11
65
1.71
0.83
1.3
1.3
—
—
—
0
0
11
65
1.71
0.83
1.3
1.3
—
—
—
0
0
12
73
1.66
0.82
3.2
1.8
—
—
—
0
0
61
504
1.24
0.80
4.4
4.1
30.3
31.5
%
0.47
40
346
16
106
1.53
0.79
1.3
1.2
—
—
—
0
0
423
4091
1.18
0.77
17.0
13.2
40.4
40.4
%
0.01
303
3144
120
1062
1.17
0.77
4.4
4.0
20.2
20.7
%
0.18
56
477
146
1312
1.16
0.77
4.8
4.6
2.0
2.3
ug/l
0.42
130
1175
36
457
0.77
0.76
1.7
1.6
—
—
—
0
0
48
388
1.26
0.76
2.3
2.4
29.0
35.8
u/l
0.90
43
336
14
91
1.55
0.76
1.2
1.1
2.0
1.6
u/ml
—
6
32
7
38
1.85
0.73
12.9
11.6
509.0
876.6
nmol/l
—
7
38
7
38
1.85
0.73
15.3
15.1
869.6
1541.6
nmol/l
—
7
38
109
961
1.17
0.73
1.8
1.5
—
—
—
0
0
7
39
1.81
0.72
2.6
3.9
—
—
—
0
0
13
84
1.56
0.72
1.2
1.4
—
—
—
0
0
33
257
1.30
0.70
1.2
1.3
—
—
—
0
0
14
93
1.52
0.70
2.8
1.7
—
—
—
0
0
9
58
1.56
0.70
1.8
1.6
—
—
—
0
0
72
616
1.20
0.69
3.4
2.7
3.2
2.1
e6/l
0.31
37
338
5
27
1.86
0.68
3.0
1.2
—
—
—
0
0
5
27
1.86
0.68
3.0
1.2
—
—
—
0
0
13
191
0.67
0.68
1.2
1.5
—
—
—
0
0
7
44
1.60
0.65
1.0
1.2
—
—
—
0
0
14
95
1.49
0.64
2.8
1.7
—
—
—
0
0
5
29
1.73
0.64
2.6
3.3
—
—
—
0
0
13
87
1.51
0.64
1.2
1.4
97.3
109.2
u/ml
—
8
18
8
52
1.55
0.59
1.0
1.1
—
—
—
0
0
14
97
1.46
0.59
1.6
1.2
—
—
—
0
0
110
989
1.14
0.58
2.0
2.3
—
—
—
0
0
12
81
1.49
0.57
1.2
1.1
1.1
2.1
u/ml
—
7
40
11
74
1.50
0.53
1.2
1.1
—
—
—
0
0
10
66
1.53
0.53
1.8
2.0
13.0
13.1
%
—
10
66
124
1132
1.13
0.52
1.6
1.7
1.5
1.4
mmol/l
0.60
98
974
13
179
0.72
0.51
1.2
1.4
—
—
—
0
0
13
179
0.72
0.51
1.2
1.4
—
—
—
0
0
13
179
0.72
0.51
1.2
1.4
—
—
—
0
0
13
179
0.72
0.51
1.2
1.4
—
—
—
0
0
16
118
1.37
0.50
1.5
1.5
—
—
—
0
0
29
236
1.24
0.48
1.7
1.4
—
—
—
0
0
10
68
1.48
0.47
1.4
3.2
—
1121.2
—
0
6
12
85
1.42
0.47
1.9
6.5
—
145.1
—
0
12
5
31
1.62
0.43
1.2
1.4
—
—
—
0
0
5
31
1.62
0.43
2.2
1.3
—
—
—
0
0
8
56
1.44
0.42
1.5
1.6
—
—
—
0
0
31
366
0.84
0.39
3.5
4.3
5.9
37.6
ug/l
0.79
21
294
26
215
1.22
0.39
1.4
1.6
—
—
—
0
0
9
66
1.37
0.38
3.6
1.8
—
—
—
0
0
9
69
1.31
0.37
1.0
1.1
11.1
29.9
u/l
—
9
61
84
769
1.11
0.35
2.9
2.9
0.8
0.7
ug/l
0.22
55
488
13
163
0.79
0.30
1.5
1.7
—
—
—
0
0
7
56
1.25
0.29
1.0
1.0
—
—
—
0
0
21
176
1.20
0.29
1.5
1.8
—
—
—
0
0
18
150
1.21
0.26
2.2
8.0
1.7
1.6
%
0.08
18
142
19
223
0.85
0.25
1.3
1.4
—
—
—
0
0
0
11
0.00
0.21
0.0
1.5
—
—
—
0
0
0
10
0.00
0.21
0.0
1.3
—
—
—
0
0
0
13
0.00
0.21
0.0
1.0
—
—
—
0
0
21
183
1.15
0.20
1.4
1.4
—
—
—
0
0
6
48
1.25
0.20
2.0
1.7
—
—
—
0
0
52
482
1.09
0.19
1.6
3.3
5.3
7.8
umol/l
1.89
39
423
16
139
1.16
0.16
1.7
1.7
—
—
—
0
0
34
313
1.09
0.15
2.1
1.8
—
—
—
0
0
9
81
1.11
0.15
1.2
1.6
—
—
—
0
0
42
395
1.07
0.12
2.1
1.9
—
—
—
0
0
12
136
0.88
0.11
1.3
1.3
—
—
—
0
0
5
61
0.82
0.08
1.0
1.4
—
—
—
0
0
5
60
0.83
0.08
1.0
1.4
—
—
—
0
0
5
62
0.80
0.08
1.0
1.4
—
—
—
0
0
5
62
0.80
0.08
1.0
1.4
—
—
—
0
0
5
62
0.80
0.08
1.0
1.4
—
—
—
0
0
5
62
0.80
0.08
1.0
1.4
—
—
—
0
0
7
65
1.08
0.08
1.1
1.2
—
—
—
0
0
14
153
0.91
0.07
1.5
1.6
—
—
—
0
0
9
105
0.85
0.06
1.0
1.4
—
—
—
0
0
32
328
0.97
0.02
1.5
1.5
—
—
—
0
0
19
183
1.04
0.01
1.5
1.3
127.0
219.0
miu/ml
—
6
93
16
155
1.03
0.00
2.1
1.7
—
—
—
0
0
16
161
0.99
0.00
3.2
1.9
—
—
—
0
0
0
6
0.00
0.00
0.0
1.5
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
65.7
—
0
6
0
5
0.00
0.00
0.0
1.2
—
—
—
0
0
0
7
0.00
0.00
0.0
1.1
—
—
—
0
0
0
7
0.00
0.00
0.0
1.1
—
—
—
0
0
0
7
0.00
0.00
0.0
1.1
—
—
—
0
0
7
71
0.99
0.00
1.0
1.1
—
—
—
0
0
0
7
0.00
0.00
0.0
1.7
—
—
—
0
0
7
71
0.99
0.00
1.1
1.2
—
—
—
0
0
6
66
0.91
0.00
1.8
3.0
16.7
18.6
u/ml
—
6
66
0
5
0.00
0.00
0.0
2.0
—
—
—
0
0
0
5
0.00
0.00
0.0
1.2
—
—
—
0
0
8
85
0.94
0.00
1.1
1.8
—
—
—
0
0
0
8
0.00
-0.00
0.0
2.6
—
81.9
—
0
8
0
8
0.00
-0.00
0.0
1.5
—
—
—
0
0
0
8
0.00
-0.00
0.0
2.1
—
—
—
0
0
Mortality – FinRegistry
↥Association
Association between endpoint F5_HYPERSOMNIA and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| F5_HYPERSOMNIA | 1.495 [1.17, 1.91] | 0.001 |
| Birth year | 0.995 [0.99, 1.0] | 0.241 |
During the follow-up period (1.1.1998 — 31.12.2019), 112 out of 1255 females with F5_HYPERSOMNIA died.
Males
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| F5_HYPERSOMNIA | 1.255 [1.08, 1.45] | 0.003 |
| Birth year | 0.986 [0.98, 1.0] | 0.005 |
During the follow-up period (1.1.1998 — 31.12.2019), 206 out of 1339 males with F5_HYPERSOMNIA died.
Mortality risk
Mortality risk for people of age
years, who have F5_HYPERSOMNIA.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.177% | 0.207% |
| 5 | 0.948% | 1.378% |
| 10 | 2.469% | 3.501% |
| 15 | 4.569% | 6.807% |
| 20 | 7.849% | 11.469% |
Relationships between endpoints
↥Index endpoint: F5_HYPERSOMNIA – Hypersomnia
GWS hits: 1
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data